1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

LXRX
Lexicon Pharmaceuticals, Inc.US flagNASDAQ Global Select
2.24
USD
-0.02
- -
995.00MMarket Cap
Lexicon Pharmaceuticals, Inc.
LXRX
(NASDAQ Global Select)

Recent

price

2.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.11
0.04
0.02
0.03
0.3
1.26
0.76
0.87
0.6
3.03
0.22
- -
- -
0.01
0.1
0.14
0.11
Revenue per Share
-2.35
-2.39
-1.58
-1.42
-1.31
-0.05
-1.27
-1.17
-1.14
1.23
-0.53
-0.6
-0.62
-0.8
-0.63
-0.14
-0.16
Basic EPS, GAAP
-1.93
-1.83
-1.36
-1.27
-0.99
1.77
-1.69
-1.76
-1.41
1.07
-1.29
-0.61
-0.54
-0.73
-0.56
-0.19
-0.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.12
4.34
3.64
2.32
2.74
2.76
1.51
0.65
-0.25
1.1
1.11
0.76
0.62
0.38
0.4
0.3
0.39
Book Value per Share
3.09
2.91
2.3
0.98
1.8
1.81
0.57
-0.27
-1.14
0.5
0.79
0.46
0.38
0.2
0.28
0.17
0.29
Tangible Book Value per Share
43
49
70
73
76
104
104
105
106
106
111
146
166
221
320
363
391
Basic Weighted Avg Shares
5
2
1
2
23
130
79
92
63
322
24
- -
- -
1
31
50
41
Sales/Revenue/Turnover
-1,895.03
-5,804.71
-9,047.57
-4,706.62
-375.58
8.45
-161.34
-140.17
-163.39
52.81
-745.09
-29,224.83
-72,489.21
-14,264.95
-634.2
-98.21
-131.43
Operating Margin (%)
5
5
4
3
2
1
2
3
4
4
3
- -
- -
1
1
1
- -
Depreciation Expense
-102
-116
-110
-104
-100
-5
-131
-123
-121
130
-59
-88
-102
-177
-200
-50
-61
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2,073.66
-6,285.29
-10,120.39
-4,686.14
-438.85
-3.6
-165.85
-134.14
-190.71
40.4
-244.11
-29,448.99
-73,341.01
-14,710.88
-644.78
-101.08
-147.38
Profit Margin (%)
204
264
213
115
324
409
193
217
137
272
111
67
118
145
201
81
182
Working Capital
27
23
22
20
88
101
85
232
244
234
1
1
54
105
107
57
58
LT Debt
247
298
267
170
284
286
157
68
-26
117
156
114
117
93
146
108
175
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-49.55
-42.68
-39.06
-47.67
-44.16
-1.64
-59.31
-109
- -
- -
-42.84
-65.01
-88.37
-168.5
-167.66
-39.72
-40.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
2
2
LT Borrowings
49
50
51
LT Finance Leases
7
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
363
424
445
Market Capitalization
418
661
1,068

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
102
186
197
Cash, Cash Equivalents & STI
96
171
191
Accounts Receivable, Net
2
12
2
Inventories
- -
- -
1
Total Current Liabilities
21
10
15
Payables & Accruals
8
6
9
ST Debt
6
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-76.45%
-2.86%
-26.32%
Free Cash Flow
-61.99%
-1.52%
-62.27%
Net Income, GAAP
242.41%
15.6%
-74.88%
Sales/Revenue/Turnover
341.84%
631.16%
60.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
2
2
27
31
2025
1
29
14
5
50
2026
21
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.17
-0.18
-0.09
-0.63
2025
-0.07
0.01
-0.04
-0.04
-0.14
2026
- -
-0.07
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
AveXis, Inc. (AVXS)
Allarity Therapeutics, Inc. (ALLR)
Jazz Pharmaceuticals plc (JAZZ)
PDS Biotechnology Corporation (PDSB)
Clarus Therapeutics Holdings, Inc. (CRXWQ)
Mabpharm Limited (2181.HK)
Business
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company focused on discovering and developing treatments for diabetes, metabolic disorders, and other chronic diseases through its proprietary gene knockout technology. The company offers a pipeline of investigational drug candidates, including sotagliflozin (brand name Inpefa), an SGLT1 and SGLT2 dual inhibitor approved for heart failure and chronic kidney disease in type 2 diabetes patients; LX9211, a central nervous system-penetrant EP2 receptor antagonist in Phase 2 trials for neuroinflammation-related conditions; LX9851, a peripherally restricted EP2 antagonist for peripheral inflammatory diseases; and earlier-stage programs targeting neuropathic pain, obesity, and hypoparathyroidism. Founded in 1994 and headquartered in The Woodlands, Texas, Lexicon operates primarily in the United States with clinical trials conducted globally. Recent developments include positive Phase 3 trial results for Inpefa in expanding indications announced in late 2024, a strategic licensing partnership with Novo Nordisk for LX9211 development in 2025, and a $100 million financing round closed in Q3 2025 to support pipeline advancement and manufacturing scale-up.

Company News

Company News APIChatGPT

  • globenewswire.com

    Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

  • globenewswire.com

    Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

  • globenewswire.com

    Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

  • seekingalpha.com

    Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

  • marketbeat.com

    Lexicon Pharmaceuticals Q2 Earnings Call Highlights

  • seekingalpha.com

    Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

  • zacks.com

    Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

  • globenewswire.com

    Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

  • globenewswire.com

    Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

  • globenewswire.com

    Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

  • zacks.com

    Here's Why You Should Add LXRX Stock to Your Portfolio Now

  • fool.com

    Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

  • globenewswire.com

    Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

  • globenewswire.com

    Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

  • globenewswire.com

    Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

  • marketbeat.com

    Lexicon Pharmaceuticals Q1 Earnings Call Highlights

  • seekingalpha.com

    Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

  • zacks.com

    Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

  • globenewswire.com

    Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

  • globenewswire.com

    Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital